The ASX 200 closed lower on Friday, marking its seventh consecutive session of losses. The index fell 1.56%, continuing a downward trend influenced by global AI stock declines, weaker gold prices, and broader economic concerns. Among the top gainers, Telix Pharma rose 3.23%, driven by positive developments related to the FDA. Despite the overall market decline, some stocks saw gains, highlighting the mixed performance within the index. The ongoing economic uncertainty has contributed to the prolonged downturn, with investors reacting to shifting market conditions. Analysts note that the decline reflects broader global financial pressures, impacting Australian equities. The situation underscores the challenges faced by the market in a volatile economic environment.
ASX 200 recule à sept séances consécutives





























